<DOC>
	<DOCNO>NCT01634750</DOCNO>
	<brief_summary>Background : - Hereditary inclusion body myopathy ( HIBM ) genetic disorder cause mutation gene call GNE . This gene responsible produce sugar call sialic acid . Low level sialic acid may cause muscle problem . Symptoms HIBM include walk difficulty muscle weakness , usually start person 20 30 become bad time . Researchers study drug call ManNAc . It may useful treat HIBM . However , drug still test . Researchers want see ManNAc absorbed remove blood . They look specifically whether ManNAc stop slow symptom HIBM . Objectives : - &lt; TAB &gt; To study MaNAc absorbed remove blood people HIBM . - &lt; TAB &gt; To study safety ManNAc people HIBM . Eligibility : - Individuals 18 70 year age HIBM . Design : - Participants screen physical exam medical history . Blood urine sample collect . - Participants 3 4-day inpatient stay main part study . - Participants divide group six . In group , four take ManNAc two take placebo . Participants know one receive . - Participants single dose either ManNAc placebo . They monitor possible side effect . Frequent blood sample collect 4-day stay . - No treatment HIBM provide part study .</brief_summary>
	<brief_title>Phase I Clinical Trial ManNAc Patients With GNE Myopathy Hereditary Inclusion Body Myopathy ( HIBM )</brief_title>
	<detailed_description>Hereditary inclusion body myopathy ( HIBM ) autosomal recessive , neuromuscular disorder characterize progressive muscle weakness onset early adulthood . The causative gene , GNE , cod bifunctional enzyme uridine diphospho-N-acetylglucosamine ( UDP-GlcNAc ) -2-epimerase/N-acetylmannosamine ( ManNAc ) kinase ( GNE/MNK ) , catalyze first 2 step biosynthesis sialic acid . The subsequent paucity sialic acid production presume cause decrease sialylation HIBM muscle glycoprotein , result muscle deterioration . In Phase 1 , randomize , placebo-controlled , double-blind , escalate single-dose study , propose provide ManNAc ( N-acetyl-D-mannosamine monohydrate ) orally liquid solution 3 cohort 6 subject ( Cohorts A , B , C ) dose 3,000 mg , 6,000 mg , 10,000 mg ManNAc , respectively , maximum tolerate dose ( MTD ) . The objective study evaluate safety , tolerability , pharmacokinetics ( PK ) single dose orally administer ManNAc HIBM subject , identify MTD single dose orally administer ManNAc HIBM subject , explore effect single dose ManNAc potential pharmacodynamic ( PD ) marker HIBM . All subject randomly assign 2:1 ratio receive ManNAc ( n equal 4 ) placebo ( n equal 2 ) decision dose-escalate responsibility Safety Review Committee ( SRC ) . Safety assess adverse event ( AEs ) , clinical laboratory test , vital sign , physical examination , electrocardiogram ( ECGs ) . PK assess ManNAc sialic acid .</detailed_description>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Distal Myopathies</mesh_term>
	<criteria>INCLUSIONI CRITERIA : Subject 1870 year , either gender , inclusive . Subject diagnosis HIBM ( IBM2 , GNE myopathy , DMRV Nonaka myopathy ) base upon consistent clinical course identification 2 GNE mutation . Molecular confirmation diagnosis obtain subject study . Subject must willing stop treatment ManNAc , sialic acid , IVIG , and/or supplement contain sialic acid ( eg , St John wort , sialyllactose ) 30 day prior randomization remain treatment duration trial . Subject ability travel NIH Clinical Center ( CC ) admission . Subject ( woman reproductive age ) must willing use effective method contraception duration trial . Subject provide write informed consent . EXCLUSION CRITERIA : Subject severe disease manifestation would interfere ability comply requirement protocol . Subject psychiatric illness neurological disease would interfere ability comply requirement protocol . This include , limited , uncontrolled/untreated psychotic depression , bipolar disorder , schizophrenia , substance abuse dependence , antisocial personality disorder , panic disorder . Subject hepatic laboratory parameter ( AST , ALT , GGTP ) , renal laboratory parameter ( creatinine , BUN ) great 3 time upper limit normal . Subject QTcB &gt; 450 msec ( male ) QTcB &gt; 470 msec ( female ) . Subject anemic ( define two standard deviation normal age gender ) . Subject show evidence clinically significant cardiovascular , pulmonary , hepatic , renal , hematological , metabolic , gastrointestinal disease , condition require immediate surgical intervention . Subject pregnant breastfeeding time study . Subject receive treatment another investigational drug , investigational device , approve therapy investigational use within 4 week initial screening . Subject hypersensitivity ManNAc judgment investigator , condition place subject increase risk adverse effect .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 24, 2017</verification_date>
	<keyword>N-Acetyl-D-mannosamine ( ManNAc )</keyword>
	<keyword>HIBM</keyword>
	<keyword>GNE Myopathy</keyword>
</DOC>